814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3-Reference-Cited by-同舟云学术

814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3

Published:2022-09 Issue: Volume:33 Page:S918-S919
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Migden M.R.,Schmults C.,Khushanlani N.,Guminski A.,Chang A.L.,Lewis K.,Ansstas G.,Bowyer S.E.,Hughes B.G.M.,Schadendorf D.,Modi B.,Dunn L.,Flatz L.,Hauschild A.,Yoo S-Y.,Booth J.,Seebach F.,Lowy I.,Fury M.G.,Rischin D.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates in the Management of Advanced Nonmelanoma Skin Cancer;Surgical Oncology Clinics of North America;2024-10

2. Managing large cutaneous squamous cell carcinoma with programmed cell death protein 1 inhibitor monotherapy: Real-world experience at a single center;JAAD International;2024-09

3. Successful Treatment of Cutaneous Squamous Cell Cancer with Cemiplimab—A Report of Two Cases Demonstrating the Management of Pseudoprogression and Adverse Events;Journal of Clinical Medicine;2024-07-19

4. Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab);Frontiers in Immunology;2024-07-12

5. Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy;Cancer Immunology, Immunotherapy;2024-05-07